Drug intelligence / Profile preview

FCHO

Development stage: Preclinical
Lead developer: Clinical Nutrition Research Center, Illinois Institute of Technology
Modality: Microbiome Therapeutics
Administration: Oral

Overview

FCHO is a specific dietary fiber under investigation for its fermentability and potential health benefits, particularly in glucose control. It is administered orally as a dietary supplement and is being studied for its tolerability when consumed over a period of 7 days. The research aims to provide evidence for its fermentability and gather information on its potential to improve glucose regulation.

Targets

FABP4 (Fatty acid-binding protein 4)

Beyond the preview

Go deeper on FCHO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCHO.

Explore the full profile